keyword
https://read.qxmd.com/read/38644691/comprehensive-analysis-of-n6-methylandenosine-related-lncrnas-in-clear-cell-renal-cell-carcinoma-a-correlation-with-prognosis-tumor-progression-and-therapeutic-response
#21
JOURNAL ARTICLE
Chang Meng, Juan Li, Xiang Wang, Yicen Ying, Zhihua Li, Aixiang Wang, Xuesong Li
This study aims to develop a prognostic signature based on m6A-related lncRNAs for clear cell renal cell carcinoma (ccRCC). Differential expression analysis and Pearson correlation analysis were used to identify m6A-related lncRNAs associated with patient outcomes in The Cancer Genome Atlas (TCGA) database. Our approach led to the development of an m6A-related lncRNA risk score (MRLrisk), formulated using six identified lncRNAs: NFE4, AL008729.2, AL139123.1, LINC02154, AC124854.1 and ARHGAP31-AS1. Higher MRLrisk was identified as a risk factor for patients' prognosis in ccRCC...
April 21, 2024: Cancer Investigation
https://read.qxmd.com/read/38644181/-calcified-amorphous-tumor-diagnosed-after-stroke-report-of-a-case
#22
JOURNAL ARTICLE
Shingo Tsushima, Toshiyuki Maeda, Shinji Nakashima, Satoshi Muraki, Taku Sakurada, Jun Sasaki, Eiji Araki
Calcified amorphous tumor (CAT), a non-neoplastic tumor, is rare. Histopathologic features are the presence of calcified nodules in an amorphous background of fibrin. CAT is reported to be associated with renal dysfunction or hemodialysis, and possibly causes cerebral embolism. We report a case of CAT diagnosed after stroke. A 58-year-old male with a 2-year history of hemodialysis was diagnosed with an acute stroke, and was treated medically. Paralysis promptly improved, but transthoracic echocardiography revealed a tumor attached to the posterior mitral leaflet and dense mitral annular calcification...
April 2024: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://read.qxmd.com/read/38644109/preoperative-risk-calculator-for-the-probability-of-completing-nephron-sparing-for-kidney-cancer
#23
JOURNAL ARTICLE
Francesco Cei, Alessandro Larcher, Giuseppe Rosiello, Giuseppe Basile, Giacomo Musso, Chiara Re, Giuseppe Fallara, Federico Belladelli, Giorgio Brembilla, Giorgia Guazzarotti, Francesco De Cobelli, Laura Marandino, Andrea Necchi, Alberto Briganti, Andrea Salonia, Roberto Bertini, Francesco Montorsi, Umberto Capitanio
PURPOSE: In absence of predictive models, preoperative estimation of the probability of completing partial (PN) relative to radical nephrectomy (RN) is invariably inaccurate and subjective. We aimed to develop an evidence-based model to assess objectively the probability of PN completion based on patients' characteristics, tumor's complexity, urologist expertise and surgical approach. DESIGN, SETTING AND PARTICIPANTS: 675 patients treated with PN or RN for cT1-2 cN0 cM0 renal mass by seven surgeons at one single experienced centre from 2000 to 2019...
April 21, 2024: Urologic Oncology
https://read.qxmd.com/read/38643451/empagliflozin-protective-effects-against-cisplatin-induced-acute-nephrotoxicity-by-interfering-with-oxidative-stress-and-inflammation-in-wistar-rats
#24
JOURNAL ARTICLE
Nika Farrokh-Eslamlou, Saeideh Momtaz, Amirhossein Niknejad, Yasamin Hosseini, Parvin Mahdaviani, Morteza Ghasemnejad-Berenji, Amir Hossein Abdolghaffari
Cisplatin (Cis) is a platinum-based antineoplastic drug used in various types of cancers. This drug can induce nephrotoxicity as a cause of acute kidney injury (AKI) by inducing oxidative stress and inflammation. Empagliflozin (Empa) is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus. In addition to its blood glucose-lowering effect, Empa has been shown to exert anti-inflammatory and anti-oxidant properties...
April 21, 2024: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38643022/avoiding-needless-nephrectomy-what-is-the-role-of-small-renal-mass-biopsy-in-2024
#25
REVIEW
Bruce Gao, Antonio R H Gorgen, Rohit Bhatt, Zachary E Tano, Kalon L Morgan, Kelvin Vo, Sina Soltanzadeh Zarandi, Sohrab N Ali, Pengbo Jiang, Roshan M Patel, Ralph V Clayman, Jaime Landman
Current guidelines do not mandate routine preoperative renal mass biopsy (RMB) for small renal masses (SRMs), which results in a considerable rate (18%-26%) of needless nephrectomy/partial nephrectomy for benign renal tumors. In light of this ongoing practice, a narrative review was conducted to examine the role of routine RMB for SRM. First, arguments justifying the current non-biopsy approach to SRM are critically reviewed and contested. Second, as a standalone procedure, RMB is critically assessed; RMB was found to have higher sensitivity, specificity, and an equal or lower complication rate when compared with other commonly preoperatively biopsied solid organ tumors (e...
April 19, 2024: Urologic Oncology
https://read.qxmd.com/read/38642139/benign-metastasizing-fumarate-hydratase-fh-deficient-uterine-leiomyomas-clinicopathological-and-molecular-study-with-first-documentation-of-multi-organ-metastases
#26
JOURNAL ARTICLE
Xiaoxue Yin, Xiaoxia Wei, Ruqaiya Al Shamsi, Fatima S Ali, Faiza Al Kindi, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Mohammed Al Masqari, Linmao Zheng, Qiao Zhou, Abbas Agaimy, Ni Chen
Leiomyoma is the most prevalent benign tumor of the female reproductive system. Benign metastasizing leiomyoma (BML) is a rare phenomenon that presents at distant sites, typically the lungs, exhibiting histopathological features similar to the primary uterine tumor in the absence of malignancy features in both. Fumarate hydratase-deficient uterine leiomyoma (FH-d UL) is an uncommon subtype among uterine smooth muscle tumors (0.5-2%), showing distinctive histomorphology and FH inactivation. The majority of FH-d ULs are sporadic, caused by somatic FH inactivation, while a minority of cases occur in the context of the hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome caused by germline FH inactivation...
April 20, 2024: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/38642109/a-phase-i-trial-of-autologous-rak-cell-immunotherapy-in-metastatic-renal-cell-carcinoma
#27
JOURNAL ARTICLE
Jing Xu, Wen Zhang, Jinlian Tong, Caixia Liu, Qiaohui Zhang, Liren Cao, Jiangyong Yu, Aiping Zhou, Jie Ma
BACKGROUND: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge worldwide. Here, we introduced a phase I trial of autologous RAK cell therapy in patients with mRCC whose cancers progressed after prior systemic therapy. Although RAK cells have been used in clinic for many years, there has been no dose-escalation study to demonstrate its safety and efficacy. METHODS: We conducted a phase I trial with a 3 + 3 dose-escalation design to investigate the dose-related safety and efficacy of RAK cells in patients with mRCC whose cancers have failed to response to systemic therapy (ChiCTR1900021334)...
April 20, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38642052/chiral-pyclen-based-heptadentate-chelates-as-highly-stable-mri-contrast-agents
#28
JOURNAL ARTICLE
Yong Jian, Gengshen Mo, Weiyuan Xu, Yao Liu, Zhichao Zhang, Yinghui Ding, Ruonan Gao, Jiao Xu, Jiang Zhu, Kun Shu, Zhihan Yan, Fabio Carniato, Carlos Platas-Iglesias, Fangfu Ye, Mauro Botta, Lixiong Dai
In recent years, pyclen-based complexes have attracted a great deal of interest as magnetic resonance imaging (MRI) contrast agents (CAs) and luminescent materials, as well as radiopharmaceuticals. Remarkably, gadopiclenol, a Gd(III) bishydrated complex featuring a pyclen-based heptadentate ligand, received approval as a novel contrast agent for clinical MRI application in 2022. To maximize stability and efficiency, two novel chiral pyclen-based chelators and their complexes were developed in this study. Gd-X-PCTA-2 showed significant enhancements in both thermodynamic and kinetic stabilities compared to those of the achiral parent derivative Gd-PCTA ...
April 20, 2024: Inorganic Chemistry
https://read.qxmd.com/read/38641065/lncrna-serb-promotes-vasculogenic-mimicry-vm-formation-and-tumor-metastasis-in-renal-cell-carcinoma
#29
JOURNAL ARTICLE
Shuai Tang, Fangmin Chen, Jianghui Zhang, Fan Chang, Zheng Lv, Kai Li, Song Li, Yixi Hu, Shuyuan Yeh
A growing body of evidence shows that vasculogenic mimicry (VM) is closely related to the invasion and metastasis of many tumor cells. Although the estrogen receptor (ER) can promote initiation and progression of renal cell carcinoma (RCC), how downstream biomolecules are involved, and the detailed mechanisms of how ER expression is elevated in RCC remain to be further elucidated. Here, we discovered that LncRNA-SERB is highly expressed in tumor cells of RCC patients. We used multiple RCC cells and an in vivo mouse model for our study, and results indicated that LncRNA-SERB could boost RCC VM formation and cell invasion in vitro and in vivo...
April 17, 2024: Journal of Biological Chemistry
https://read.qxmd.com/read/38640999/omentin-reduces-venous-neointimal-hyperplasia-in-arteriovenous-fistula-through-hypoxia-inducible-factor-1-alpha-inhibition
#30
JOURNAL ARTICLE
Li Zhui, Chen Yuling, Wang Hansheng, Li Xiangjie
Arteriovenous fistula (AVF) failure often involves venous neointimal hyperplasia (VNH) driven by elevated hypoxia-inducible factor-1 alpha (HIF-1α) in the venous wall. Omentin, known for its anti-inflammatory and anti-hyperplasia properties, has an uncertain role in early AVF failure. This study investigates omentin's impact on VNH using a chronic renal failure (CRF) rabbit model. The CRF rabbit model of AVF received omentin-expressing adenoviral vector or control β-gal vector to assess omentin's effects on VNH...
April 17, 2024: Microvascular Research
https://read.qxmd.com/read/38640229/gpr1-and-cmklr1-control-lipid-metabolism-to-support-development-of-clear-cell-renal-cell-carcinoma
#31
JOURNAL ARTICLE
Dazhi Wang, Iqbal Mahmud, Vijay S Thakur, Sze Kiat Tan, Daniel G Isom, David B Lombard, Mark L Gonzalgo, Oleksandr N Kryvenko, Philip L Lorenzi, Vanina T Tcheuyap, James Brugarolas, Scott M Welford
Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, is largely incurable in the metastatic setting. ccRCC is characterized by excessive lipid accumulation that protects cells from stress and promotes tumor growth, suggesting that the underlying regulators of lipid storage could represent potential therapeutic targets. Here, we evaluated the regulatory roles of GPR1 and CMKLR1, two G-protein coupled receptors of the pro-tumorigenic adipokine chemerin that is involved in ccRCC lipid metabolism...
April 19, 2024: Cancer Research
https://read.qxmd.com/read/38639585/advances-in-tumor-management-harnessing-the-potential-of-histotripsy
#32
REVIEW
Yash Verma, Arosh S Perera Molligoda Arachchige
Tissue ablation techniques have long been used in clinical settings to treat various oncologic diseases. However, many of these techniques are invasive and can cause substantial adverse effects. Histotripsy is a noninvasive, nonionizing, nonthermal tissue ablation technique that has the potential to replace surgical interventions in various clinical settings. Histotripsy works by delivering high-intensity focused ultrasound waves to target tissue. These waves create cavitation bubbles within tissues that rapidly expand and collapse, thereby mechanically fractionating the tissue into acellular debris that is subsequently absorbed by the body's immune system...
May 2024: Radiology. Imaging cancer
https://read.qxmd.com/read/38639572/belzutifan-a-novel-therapeutic-for-the-management-of-von-hippel-lindau-disease-and-beyond
#33
REVIEW
Lauren Curry, Maryam Soleimani
The identification of the VHL gene and its role in regulating the hypoxia-inducible factor signaling pathway has helped to revolutionize the treatment of renal cell carcinoma (RCC). Belzutifan is a novel small-molecule inhibitor of hypoxia-inducible factor 2α which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease, earning regulatory approvals for this indication. There is also early evidence for efficacy in sporadic RCC. Belzutifan has a favorable safety profile. Several clinical trials are currently ongoing, which should help in identifying this promising drug's role in RCC and beyond...
April 19, 2024: Future Oncology
https://read.qxmd.com/read/38639274/integrated-bioinformatics-and-experimental-validation-to-identify-a-disulfidptosis-related-lncrna-model-for-prognostic-prediction-in-papillary-renal-cell-carcinoma
#34
JOURNAL ARTICLE
Yidong Zhu, Xiaoyi Jin, Jun Liu
AIMS: This study aimed to construct a prognostic model for papillary renal cell carcinoma (pRCC) utilizing disulfidptosis-associated long non-coding RNAs (lncRNAs). Additionally, it investigated the potential of these lncRNAs in predicting immune responses and drug sensitivity in pRCC. BACKGROUND: LncRNAs have been implicated in the progression and prognosis of pRCC. Recently, disulfidptosis, an emerging form of regulated cell death, has shown potential as a therapeutic approach for cancer...
April 18, 2024: Combinatorial Chemistry & High Throughput Screening
https://read.qxmd.com/read/38639108/quantitative-assessment-of-drug-efficacy-and-emergence-of-resistance-in-patients-with-metastatic-renal-cell-carcinoma-using-a-longitudinal-exposure-tumor-growth-inhibition-model-apitolisib-dual-pi3k-mtorc1-2-inhibitor-versus-everolimus-mtorc1-inhibitor
#35
JOURNAL ARTICLE
Anita Moein, Jin Y Jin, Matthew R Wright, Harvey Wong
Cancer remains a significant global health challenge, and despite remarkable advancements in therapeutic strategies, poor tolerability of drugs (causing dose reduction/interruptions) and/or the emergence of drug resistance are major obstacles to successful treatment outcomes. Metastatic renal cell carcinoma (mRCC) accounts for 2% of global cancer diagnoses and deaths. Despite the initial success of targeted therapies in mRCC, challenges remain to overcome drug resistance that limits the long-term efficacy of these treatments...
April 19, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38638503/towards-navigation-in-endoscopic-kidney-surgery-based-on-preoperative-imaging
#36
JOURNAL ARTICLE
Ayberk Acar, Daiwei Lu, Yifan Wu, Ipek Oguz, Nicholas Kavoussi, Jie Ying Wu
Endoscopic renal surgeries have high re-operation rates, particularly for lower volume surgeons. Due to the limited field and depth of view of current endoscopes, mentally mapping preoperative computed tomography (CT) images of patient anatomy to the surgical field is challenging. The inability to completely navigate the intrarenal collecting system leads to missed kidney stones and tumors, subsequently raising recurrence rates. A guidance system is proposed to estimate the endoscope positions within the CT to reduce re-operation rates...
2024: Healthcare Technology Letters
https://read.qxmd.com/read/38637886/the-development-of-chimeric-antigen-receptor-t-cells-against-cd70-for-renal-cell-carcinoma-treatment
#37
JOURNAL ARTICLE
Qinghui Xiong, Haiying Wang, Qiushuang Shen, Yan Wang, Xiujie Yuan, Guangyao Lin, Pengfei Jiang
In this study, we investigated CD70 as a promising target for renal cell carcinoma (RCC) therapy and developed a potent chimeric antigen receptor T (CAR-T) cells for potential clinical testing. CD70, found to be highly expressed in RCC tumors, was associated with decreased survival. We generated CAR-T cells expressing VHH sequence of various novel nanobodies from immunized alpaca and a single-chain variable fragment (scFv) derived from human antibody (41D12). In our in vitro experiments, anti-CD70 CAR-T cells effectively eliminated CD70-positive tumor cells while sparing CD70-negative cells...
April 18, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38637186/bench-to-bedside-imaging-in-brain-metastases-a-road-to-precision-oncology
#38
REVIEW
S Shukla, A Karbhari, S Rastogi, U Agarwal, P Rai, A Mahajan
Radiology has seen tremendous evolution in the last few decades. At the same time, oncology has made great strides in diagnosing and treating cancer. Distant metastases of neoplasms are being encountered more often in light of longer patient survival due to better therapeutic strategies and diagnostic methods. Brain metastasis (BM) is a dismal manifestation of systemic cancer. In the present scenario, magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET) are playing a big role in providing molecular information about cancer...
March 16, 2024: Clinical Radiology
https://read.qxmd.com/read/38637142/safety-and-efficacy-of-para-aminohippurate-coinfusion-for-renal-protection-during-peptide-receptor-radiotherapy-in-patients-with-neuroendocrine-tumors
#39
JOURNAL ARTICLE
Alexandros Moraitis, Walter Jentzen, Pedro Fragoso Costa, David Kersting, Stephan Himmen, Marta Coelho, Marian Meckel, Cees J A van Echteld, Wolfgang P Fendler, Ken Herrmann, Miriam Sraieb
Para -aminohippurate, also known as p -aminohippuric acid (PAH), is used clinically to measure effective renal plasma flow. Preclinically, it was shown to reduce 177 Lu-DOTATOC uptake in the kidneys while improving bioavailability compared with amino acid (AA) coinfusion. We report the safety and efficacy of PAH coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors. Methods: Twelve patients with metastatic or unresectable gastroenteropancreatic neuroendocrine tumors received 177 Lu-DOTATOC in 33 treatment cycles...
April 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38637140/a-systematic-review-on-the-diagnostic-value-of-fibroblast-activation-protein-inhibitor-pet-ct-in-genitourinary-cancers
#40
JOURNAL ARTICLE
Marinus J Hagens, Pim J van Leeuwen, Maurits Wondergem, Thierry N Boellaard, Francesco Sanguedolce, Daniela E Oprea-Lager, Axel Bex, André N Vis, Henk G van der Poel, Laura S Mertens
In contemporary oncologic diagnostics, molecular imaging modalities are pivotal for precise local and metastatic staging. Recent studies identified fibroblast activation protein as a promising target for molecular imaging across various malignancies. Therefore, we aimed to systematically evaluate the current literature on the utility of fibroblast activation protein inhibitor (FAPI) PET/CT for staging patients with genitourinary malignancies. Methods: A systematic Embase and Medline search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process, on August 1, 2023...
April 18, 2024: Journal of Nuclear Medicine
keyword
keyword
15412
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.